參考文獻

［1］TEEDE HJ，MISSO ML，BOYLE JA，et al.Translation and implementation of the Australian-led PCOS guideline:clinical summary and translation resources from the International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.Medical Journal of Australia，2018，209（7）:S3-23.

［2］AGNES，A.The importance of restoring body fat mass in the treatment of anorexia nervosa:an expert commentary.J Popul Ther Clin Pharmacol，2019，26（3）:e9-e13.

［3］GORDON CM，ACKERMAN KE，BERGA SL，et al.Functional hypothalamic amenorrhea:an endocrine society clinical practice guideline.J Clin Endocrinol Metab，2017，102（5）:1413-1439.

［4］Collaborative Group on Hormonal Factors in Breast Cancer.Type and timing of menopausal hormone therapy and breast cancer risk:individual participant meta-analysis of the worldwide epidemiological evidence.Lancet，2019，394（10204）:1159-1168.

［5］TRANOULIS A，LAIOS A，PAMPANOS A，et al.Efficacy and safety of pulsatile gonadotropin-releasing hormone therapy among patients with idiopathic and functional hypothalamic amenorrhea:a systematic review of the literature and a meta-analysis.Fertil Steril，2018，109（4）:708-719.

［6］ALVES ED，BONFáA LO，PIGATTO GR，et a1.Photobiomodulation can improve ovarian activity in polycystic ovary syndrome-induced rats.J Photochem Photobiol B，2019，194:6-13.

［7］LIZNEVA D，SUTURINA L，WALKER W，et al.Criteria，prevalence，and phenotypes of polycystic ovary syndrome.Fertil Steril，2016，106（1）:6-15.

［8］潘燁 ，王澤 ，馮海英 ，等 .來曲唑促排卵研究進展 .中國實用婦科與產科雜志 ，2018，34（3）:340-343.

［9］李萌，阮祥燕.多囊卵巢綜合征的診斷治療與管理.中國醫(yī)刊，2018，53（5）:465-468.

［10］楊紹玲，李鴻.促性腺激素釋放激素脈沖泵治療的應用及進展.國際內分泌代謝雜志 ，2018，38（2）:124-127.

［11］胡淑敏　，冷義福 ，牟琳琳 ，等 .生長激素在薄型子宮內膜患者凍融胚胎移植周期內膜準備中應用的臨床研究.中華生殖與避孕雜志 ，2019，39（12）:963-967.

［12］ROSENFIELD RL，EHRMANN DA.The Pathogenesis of Polycystic Ovary Syndrome（PCOS）:The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.Endocr Rev，2016，37（5）:467-520.

［13］FENG Q，GAO B，HUANG H，et al.Growth hormone promotes human endometrial glandular cells proliferation and motion through the GHR-STAT3/5 pathway.Ann Transl Med，2020，8（4）:53.

［14］CHAPLIN A，CARPéNé C，MERCADER J.Resveratrol，Metabolic Syndrome，and Gut Microbiota.Nutrients，2018，10（11）:1651.